Updating Women's Health Access: Regulatory Reforms Needed for Innovation in Canada

The Urgent Need for Regulatory Reforms in Women's Health in Canada

In a striking collaboration, Duchesnay and PeriPharm published a groundbreaking article in the Journal of Obstetrics and Gynaecology Canada (JOGC), shining a light on the alarming delays that Canadian women face when accessing innovative medications for their health. This collective effort aims to incite necessary changes in regulatory and reimbursement policies that govern women's health treatment in Canada.

Duchesnay, a Canadian pharmaceutical firm renowned for its dedication to women's health, alongside PeriPharm, which specializes in pharmacoeconomics and outcomes research, conducted a meticulous analysis exploring the access issues within the sector over the last 20 years (from 2003 to 2023). The findings from their research were presented at the Femtech Canada Forum held in Vancouver, revealing that access to innovations in women's health lags significantly behind that of other medications.

Key Findings and Implications

The detailed investigation uncovered multiple concerning trends. Notably, public coverage of women’s health medications is approximately one year behind that of other pharmaceutical products, leaving many women dependent on private insurance for necessary treatments. According to Rachel Bartholomew, Founder and Lead Advisor of Femtech Canada, these discrepancies manifest real challenges for women seeking timely options already available globally.

Incredibly, from 2003 to 2023, of the 45 women's health medications approved by the U.S. Food and Drug Administration (FDA), only 24 gained approval in Canada. Moreover, even successful approvals do not guarantee swift integration into public drug programs; it takes an average of over three years for newly approved women's health medications to appear on a public formulary. This delay is strikingly a year longer than the approval timeline for other classifications of medications. Alarmingly, fewer than two-thirds of women's health treatments sanctioned by Health Canada receive reimbursement through public health plans.

The Call for Change

The article's co-author, Catherine Beauchemin, Ph.D., from PeriPharm, emphasizes that prompt access to innovative therapies must be prioritized in Canada's regulatory framework. She hopes that highlighting these deficiencies will drive the creation of patient-centered policies that enhance the quality of care women receive.

Édith Sirard, Director of Sales and Marketing at Duchesnay and another co-author, echoes the urgency of modernizing the regulatory landscape to enable better access for women to effective therapies. She voices a prevalent sentiment that for women to achieve their full potential, those in charge must prioritize health needs and ensure the availability of the best treatments.

Historical Context and Persistent Challenges

The findings resonate with previous studies, notably an analysis by Azzarello D and Collins J in 2004, which reported that Canadian women had access to only 37% of the hormonal contraceptive options available worldwide. This troubling statistic highlights that despite advancements in global healthcare, access within Canada has remained dormant over two decades, underscoring a critical need for reform.

A Vision for Future Improvements

The current study not only sheds light on existing challenges but also aims to serve as a catalyst for comprehensive revisions in regulatory policies. It advocates for better incorporation of patient experiences, acknowledgment of women’s specific health needs, and more effective collaboration amongst federal and provincial healthcare decision-makers. Without targeted reforms, the persistent barriers to innovation in women’s health may continue.

Conclusion

The collaboration between Duchesnay and PeriPharm represents an essential step towards addressing the substantial gaps in women's health access in Canada. As stakeholders push for more equitable healthcare policies, the onus will be on government bodies to act promptly and decisively, ensuring that women across the country can benefit from the advancements in medical science. Only then can Canada hope to offer its women the optimal standard of care they deserve and have long been denied.